Short-term adverse effects/toxicity

Toxicity The intrinsic capability of a chemical or substance to cause injury or adverse effects to animals, humans, or plants. Acute toxicity involves harmful effects caused by chemical substances in an organism through a single or short-term exposure. Chronic toxicity is the ability of a chemical substance or mixture of substances to cause harmful effects over an extended period. Subchronic toxicity is the ability of the chemical substance to cause effects for more than 1 year but less than the lifetime of the exposed organism... 

Chloroparaffines are stable, persistent compounds that bioaccumulate in the environment with BCF about 1,000. Short- and medium-chain paraffines are very toxic to aquatic organisms and may cause long-term adverse effects in the aquatic environment [134]. 

Acute Toxicity Studies. These studies should provide the following information the nature of any local or systemic adverse effects occurring as a consequence of a single exposure to the test material an indication of the exposure conditions producing the adverse effects, in particular, information on dose—response relationships, including minimum and no-effects exposure levels and data of use in the design of short-term repeated exposure studies. 

Because of the high toxicity of pyrethroids to aquatic invertebrates, these organisms are likely to be adversely affected by contamination of surface waters. Such contamination might be expected to have effects at the population level and above, at least in the short term. In one study of a farm pond, cypermethrin was applied aerially, adjacent to the water body (Kedwards et al. 1999a). Changes were observed in the composition of the macroinvertebrate community of the pond that were related to levels of the pyrethroid in the hydrosoil. Diptera were most affected, showing a decline in abundance with increasing cypermethrin concentration. Chironimid larvae first declined and later recovered. 

Federal agencies such as the FDA and EPA require a battery of toxicity tests in laboratory animals to determine an additive s or a pesticide s potential for causing adverse health effects, such as cancer, birth defects, and adverse effects on the nervous system or other organs. Tests are conducted for both short-term (acute) and long-term (chronic) toxicity. For chronic effects other than cancer, laboratory animals are exposed to different doses to determine the level at which no adverse effects occur. This level is divided by an uncertainty or safety factor (usually 100) to account for the uncertainty of extrapolating from laboratory animals to humans and for individual human differences in... 

Kramer, H.J., W.A. van den Ham, W. Slob, and M.N. Pieters. 1996. Conversion factors estimating indicative chronic no-observed-adverse-effect levels from short-term toxicity data. Regul. Toxicol. Pharmacol. 23 249-255. 

There are of course many mathematically complex ways to perform a risk assessment, but first key questions about the biological data must be resolved. The most sensitive endpoint must be defined along with relevant toxicity and dose-response data. A standard risk assessment approach that is often used is the so-called divide by 10 rule . Dividing the dose by 10 applies a safety factor to ensure that even the most sensitive individuals are protected. Animal studies are typically used to establish a dose-response curve and the most sensitive endpoint. From the dose-response curve a NOAEL dose or no observed adverse effect level is derived. This is the dose at which there appears to be no adverse effects in the animal studies at a particular endpoint, which could be cancer, liver damage, or a neuro-behavioral effect. This dose is then divided by 10 if the animal data are in any way thought to be inadequate. For example, there may be a great deal of variability, or there were adverse effects at the lowest dose, or there were only tests of short-term exposure to the chemical. An additional factor of 10 is used when extrapolating from animals to humans. Last, a factor of 10 is used to account for variability in the human population or to account for sensitive individuals such as children or the elderly. The final number is the reference dose (RfD) or acceptable daily intake (ADI). This process is summarized below. 

Because of the first of these uncertainties (the extrapolation across species), assessments of risks to human health apply an uncertainty or safety factor of 100 to the experimentally derived no observed adverse effect concentration (NOAEC), in other words the NOAEC is divided by 100 to derive a no-effect level for human toxicity. This factor has been used since 1961, when it was chosen on an essentially arbitrary basis (RCEP, 2003, p22). In the assessment of risks to the environment, application factors of 10, 50, 100 or 1000 are applied to the results of tests carried out on specific species,2 depending on the species used and whether the tests were long term or short term. Evidence to the Royal Commission on Environmental Pollution (RCEP) for their report Chemicals in products indicated that these are merely extrapolation factors — they express the statistical variability of test results but do not effectively take into account inter-species variability, the vulnerability of threatened species, lifetime exposures or the complexity of biological systems... 

PYA copolymer Bioavailability enhancer Single-dose toxicity (in rat and dog) and maximum tolerated dose/short-term (2wks—oral) (in rat and dog) toxicity as well as 2 in vitro and 1 in vivo genotoxicity studies. ADME studies with 14C-labelled material are underway and a 3-6 mo toxicity study in the rat is planned No adverse effects seen to date 41... 

Results of acute, short-term and long-term toxicity studies, reproduction studies, developmental studies, genotoxicity studies, and studies of the toxicity of metabolites and impurities, and other adverse effects. Data on human toxicology, the no observable effect level, acceptable daily intake, and proposed and safety directions... 

In terms of the mechanisms of action, the pyrrolidones partition well into human horny layer. They may act by altering the solvent nature of the membrane and pyrrolidones have been used to generate reservoirs within skin membranes. Such a reservoir effect offers potential for sustained release of a permeant from the stratum corneum over extended time periods. However, as with many other potential enhancers, clinical use of pyrrolidones is problematic due to adverse reactions. An in vivo vasoconstrictor bioavailability study demonstrated that pyrrolidones caused erythema in some volunteers, although this effect was relatively short-lived. Also, a toxic hygroscopic contact reaction to NMP has been reported recently [21]. 

---